Panacea Biotec Profile
Key Indicators
- Authorised Capital ₹ 122.34 Cr
- Paid Up Capital ₹ 22.26 Cr
- Company Age 41 Year, 19 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4,285.01 Cr
- Revenue Growth 17.51%
- Profit Growth 6.45%
- Ebitda 13.82%
- Net Worth -21.55%
- Total Assets -4.98%
About Panacea Biotec
Panacea Biotec Limited (PBL) is a leading Public Limited Indian Non-Government Company incorporated in India on 02 February 1984 and has a history of 41 years. Its registered office is in Mohali, Punjab, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 531349 and on the National Stock Exchange(NSE) under PANACEABIO.
The Corporate was formerly known as Panacea Drugs Ltd. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 122.34 Cr and a paid-up capital of Rs 22.26 Cr.
The company has closed loans amounting to ₹4,285.01 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Panacea Biotec Limited India are Vinod Goel as COMPANY SECRETARY and Devender Gupta as Cfo. Ambika Sharma, Manjula Upadhyay, Ankesh Jain, and Five other members serve as directors at the Company.
Company Details
- Location
Mohali, Punjab, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
L33117PB1984PLC022350
- Company No.
022350
- Stock Symbol
BSE : 531349 NSE : PANACEABIO
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Feb 1984
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Chandigarh
Industry
What products or services does Panacea Biotec Limited offer?
Panacea Biotec Limited offers a wide range of products and services, including Content Writing Service, Research Development Services, Pharmaceutical Medicine, Health Conditions, Bone, Joint & Muscle Care, Kidney Care.
Who are the key members and board of directors at Panacea Biotec?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Goel  | Company Secretary | 13-Jan-1999 | Current |
| Devender Gupta | CFO | 29-May-2015 | Current |
| Rajesh Jain | Managing Director | 25-Nov-2006 | Current |
| Sandeep Jain | Managing Director | 15-Nov-1984 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mukul Gupta | Director | 01-Apr-2016 | Current |
| Manjula Upadhyay | Director | 30-Mar-2015 | Current |
| Ambika Sharma | Director | 12-Mar-2024 | Current |
| Ankesh Jain | Whole-Time Director | 01-Apr-2016 | Current |
| Narotam Juneja | Director | 01-Apr-2022 | Current |
| Bhupinder Singh | Director | 08-Apr-2019 | Current |
Financial Performance of Panacea Biotec.
Panacea Biotec Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 17.51% increase. The company also saw a slight improvement in profitability, with a 6.45% increase in profit. The company's net worth observed a substantial decline by a decrease of 21.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Panacea Biotec?
In 2022, Panacea Biotec had a promoter holding of 73.59% and a public holding of 26.41%. The company had 2 Subsidiaries, 1 Joint Venture and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lt Foods LimitedAmbika Sharma is a mutual person
Dtc India LimitedManjula Upadhyay is a mutual person
The Delhi Flour Mills Company LimitedManjula Upadhyay is a mutual person
Aditya Infotech LimitedAmbika Sharma is a mutual person
Nature Bio-Foods LimitedAmbika Sharma is a mutual person
Indo Count Industries LimitedAmbika Sharma is a mutual person
Charges (Loans)
₹0
₹4,285.01 Cr
Charges Breakdown by Lending Institutions
- Others : 1510.09 Cr
- State Bank Of India : 1118.40 Cr
- Sbicap Trustee Company Limited : 934.27 Cr
- Idbi Bank Limited : 150.00 Cr
- Bank Of India : 129.00 Cr
- Others : 443.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Jan 2022 | Axis Bank Limited | ₹2.96 M | Satisfied |
| 04 Feb 2020 | Others | ₹754.44 Cr | Satisfied |
| 06 Apr 2019 | Others | ₹739.69 Cr | Satisfied |
| 14 Nov 2017 | Others | ₹5.29 Cr | Satisfied |
| 27 Dec 2014 | Sbicap Trustee Company Limited | ₹934.27 Cr | Satisfied |
How Many Employees Work at Panacea Biotec?
Panacea Biotec has a workforce of 1127 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Panacea Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Panacea Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
